| | Patient and treatment factors |
Number of men |
Number of events |
Univariate analysis
(HR with 95% CI) |
Multivariate analysis
(AHR with 95% CI) | | Unadjusted HR | value | Adjusted HR | value |
| | Age at diagnosis in years | 166104 | 3809 | 1.07 (1.066, 1.075) | <0.001 | 1.01 (1.005, 1.012) | <0.001 | PSA level in ng/mL at diagnosis
(per log unit increase) | 166104 | 3809 | 3.68 (3.56, 3.81) | <0.001 | 2.02 (1.93, 2.11) | <0.001 | | Gleason score | | | | | | | | <6 | 78385 | 334 | 1 (ref.) | — | 1 (ref.) | — | | 7 | 62545 | 834 | 3.24 (2.86, 3.68) | <0.001 | 2.58 (2.26, 2.94) | <0.001 | | 8–10 | 25174 | 2641 | 26.65 (23.78, 29.86) | <0.001 | 9.46 (8.29, 10.79) | <0.001 | | Tumor stage at diagnosis | | | | | | | | 1c | 62405 | 1341 | 1 (ref.) | — | 1 (ref.) | — | | 2a–2c | 88064 | 1584 | 0.82 (0.76, 0.88) | <0.001 | 0.96 (0.89, 1.04) | 0.34 | | 3-4 | 15635 | 884 | 2.66 (2.44, 2.89) | <0.001 | 1.56 (1.42, 1.72) | <0.001 | | Race | | | | | | | | African American | 20316 | 624 | 1.42 (1.30, 1.55) | <0.001 | 1.15 (1.05, 1.26) | 0.002 | | Other | 145788 | 3185 | 1 (ref.) | — | 1 (ref.) | — | | Year of diagnosis in years | 166104 | 3809 | 0.93 (0.90, 0.96) | <0.001 | 0.92 (0.89, 0.95) | <0.001 | | Management approach | | | | | | | | Curative | 124628 | 1142 | 1 (ref.) | — | 1 (ref.) | — | | Other Rx | 4076 | 454 | 12.5 (11.25, 13.98) | <0.001 | 4.88 (4.27, 5.59) | <0.001 | | Watchful-waiting/active surveillance | 37400 | 2213 | 6.72 (6.25, 7.22) | <0.001 | 3.23 (2.94, 3.54) | <0.001 | | History of prior cancer at time of PC diagnosis | | | | | | | | No | 164647 | 3779 | 1 (ref.) | — | 1 (ref.) | — | | Yes | 1457 | 30 | 0.86 (0.60, 1.23) | 0.41 | 0.66 (0.45, 0.97) | 0.033 |
|
|
